Ketamine for the Treatment of Depression in Parkinson's Disease
Volunteers
Health Professionals
What is the purpose of this trial?
The main purpose of this study is to examine the efficacy, safety and mechanistic underpinnings of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD.
A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
- Trial withMichael J. Fox Foundation
- Ages40 years - 70 years
- GenderBoth
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Last Updated04/24/2024
- Study HIC#2000030394